


IN THE CLAIMS

Please amend the claims as follows:

Claim 1 (Original): A cyclic tetrapeptide compound of the formula (I):



wherein


R¹ is hydrogen,

R² is lower alkyl, aryl, ar(lower)alkyl optionally substituted with one or more suitable substituent(s), heterocyclic(lower)alkyl, cyclo(lower)alkyl(lower)alkyl, lower alkylcarbamoyl(lower)alkyl, or arylcarbamoyl(lower)alkyl,

R³ and R⁴ are each independently hydrogen, lower alkyl, ar(lower)alkyl optionally substituted with one or more suitable substituent(s), heterocyclic(lower)alkyl optionally substituted with one or more suitable substituent(s) or cyclo(lower)alkyl(lower)alkyl, or

R³ and R⁴ are linked together to form lower alkylene or condensed ring, or one of R³ and R⁴ is linked to the adjacent nitrogen atom to form a ring, R⁵ is lower alkylene or lower alkenylene,

Y is



[wherein R^{Y1} is hydrogen, halogen or optionally protected hydroxy,

R^{Y2} is hydrogen, halogen, lower alkyl or phenyl, and

R^{Y3} is hydrogen or lower alkyl],

R⁸ is hydrogen or lower alkyl, and

n is an integer of 1 or 2,

providing that,

when R³ is methyl, R⁴ is methyl or ethyl, R⁵ is pentylene, R⁸ is hydrogen, n is 1, R^{Y1} is optionally substituted hydroxy, R^{Y2} is methyl and R^{Y3} is hydrogen, then R² is not unsubstituted benzyl, or a salt thereof.


Claim 2 (Original): The cyclic tetrapeptide compound of claim 1, wherein

R² is phenylcarbamoyl(lower)alkyl; lower alkylcarbamoyl(lower)alkyl; or phenyl(lower)alkyl optionally substituted with one or more suitable substituent(s) selected from the group consisting of lower alkyl, halo (lower) alkyl, lower alkoxy, ar(lower)alkoxy, cyano, hydroxy, halogen, amino, lower alkanoylamino, lower alkylsulfonylamino, aryl, cyclo(lower)alkyloxy, carboxy(lower)alkoxy, heterocyclic(lower)alkoxy; lower alkenyloxy, hydroxy(lower)alkyl, arylcarbamoyl, heterocycliccarbonyl, lower(alkyl)carbamoyl(lower)alkoxy, arylcarbamoyl(lower)alkoxy, lower (alkyl) carbamoyl(lower)alkyl, heterocyclic group, lower alkoxy carbonyl, lower alkoxy carbonyl(lower)alkoxy, lower alkylcarbamoyl, heterocycliccarbonyl(lower)alkyl, heterocycliccarbonyl(lower)alkoxy, aryl(lower)alkoxy and phenylcarbamoyl(lower)alkyl,

R³ is hydrogen or lower alkyl,

R^4 is lower alkyl or phenyl(lower)alkyl substituted with lower alkoxy,

R^5 is lower alkylene,



[wherein R^{Y1} is hydrogen or hydroxy, R^{Y2} is halogen or lower alkyl and R^{Y3} is hydrogen] and

R^8 is hydrogen or lower alkyl.

Claim 3 (Original): The cyclic tetrapeptide compound of claim 2, wherein

R^2 is phenyl (lower) alkyl substituted with a substituent selected from the group consisting of lower alkyl, halo(lower)alkyl, lower alkoxy, phenyl (lower) alkyloxy, cyano, hydroxy, halogen, amino, lower alkanoylamino, (lower)alkylsulfonylamino, phenyl, cyclo(lower)alkyloxy, carboxy(lower)alkyloxy, pyridyl(lower)alkyloxy, lower alkenyloxy, hydroxy(lower)alkyl, phenylcarbamoyl, piperidinocarbonyl, lower (alkyl) carbamoyl(lower)alkoxy, phenylcarbamoyl(lower)alkoxy, lower (alkyl)carbamoyl(lower)alkyl, pyridyl, lower alkoxycarbonyl, lower alkoxycarbonyl(lower)alkoxy, lower alkylcarbamoyl, morpholinocarbonyl(lower)alkyl, piperidinocarbonyl(lower)alkoxy, phenyl (lower) alkoxy and phenylcarbamoyl(lower)alkyl,

R^3 is lower alkyl,


R^4 is lower alkyl, and

R^5 is lower alkylene.

Claim 4 (Original): A pharmaceutical composition containing the cyclic tetrapeptide compound of any of claims 1 to 3 as an active ingredient, in association with a pharmaceutically acceptable, substantially non-toxic carrier or excipient.

Claim 5 (Original): The cyclic tetrapeptide compound of any of claims 1 to 3 for use as a medicament.

Claim 6 (Original): A histone deacetylase inhibitor comprising a cyclic tetrapeptide compound of the formula (I):



wherein


R¹ is hydrogen,

R² is lower alkyl, aryl, ar(lower)alkyl optionally substituted with one or more suitable substituent(s), heterocyclic(lower)alkyl, cyclo(lower)alkyl (lower)alkyl, lower alkylcarbamoyl(lower)alkyl or arylcarbamoyl(lower)alkyl,

R³ and R⁴ are each independently hydrogen, lower alkyl, ar (lower) alkyl a optionally substituted with one or more suitable substituent(s), heterocyclic(lower)alkyl optionally substituted with one or more suitable substituent(s) or cyclo(lower)alkyl(lower)alkyl, or

R³ and R⁴ are linked together to form lower alkylene or condensed ring, or one of R³ and R⁴ is linked to the adjacent nitrogen atom to form a ring, R⁵ is lower alkylene or lower alkenylene,

Y is.



[wherein R^{Y1} is hydrogen, halogen, optionally protected hydroxy R^{Y2} is hydrogen, halogen, lower alkyl or phenyl, and

R^{Y3} is hydrogen or lower alkyl],

R^8 is hydrogen or lower alkyl, and n is an integer of 1 or 2,


providing that,

when R^3 is methyl, R^4 is methyl or ethyl, R^5 is pentylene, R^{Y1} is optionally substituted hydroxy, R^{Y2} is methyl and R^{Y3} is hydrogen, then R^2 is not unsubstituted benzyl, or a salt thereof.

Claim 7 (Original): A method for inhibiting histone deacetylase, comprising using a cyclic tetrapeptide compound (I) of claim 6.

Claim 8 (Original): Use of a cyclic tetrapeptide compound (I) of claim 6 for the manufacture of a medicament for inhibiting histone deacetylase.

Claim 9 (Currently Amended): A pharmaceutical composition for treating or preventing inflammatory disorders, diabetes, diabetic complications, homozygous thalassemia, fibrosis, cirrhosis, acute promyelocytic leukaemia (APL), organ transplant rejections, autoimmune diseases, protozoal infections or tumors, which comprises, as an active ingredient, a cyclic tetrapeptide compound of the formula (I):




wherein

R^1 is hydrogen,

R^2 is lower alkyl, aryl, ar(lower)alkyl optionally substituted with one or more suitable substituent(s), heterocyclic(lower)alkyl, cyclo(lower)alkyl(lower)alkyl, lower alkylcarbamoyl(lower)alkyl or arylcarbamoyl(lower)alkyl,

R^3 and R^4 are each independently hydrogen, lower alkyl, ar(lower)alkyl optionally substituted with one or more suitable substituent(s), heterocyclic(lower)alkyl optionally substituted with one or more suitable substituent(s) or cyclo(lower)alkyl(lower)alkyl, or

R^3 and R^4 are linked together to form lower alkylene or condensed ring, or one of R^3 and R^4 is linked to the adjacent nitrogen atom to form a ring, R^5 is lower alkylene or lower alkenylene,



Y is

[wherein R^{Y1} is hydrogen, halogen, optionally protected hydroxy R^{Y2} is hydrogen, halogen, lower alkyl or phenyl, and

R^{Y3} is hydrogen or lower alkyl],

R^8 is hydrogen or lower alkyl, and

n is an integer of 1 or 2, providing that,

when R^3 is methyl, R^4 is methyl or ethyl, R^5 is pentylene, R^8 is hydrogen, n is 1, R^{Y1}
is optionally substituted hydroxy, R^{Y2} is methyl and R^{Y3} is hydrogen, then R^2 is not
unsubstituted benzyl,
or a salt thereof.


Claim 10 (Original): A method for treating or preventing inflammatory disorders, diabetes, diabetic complications, homozygous thalassemia, fibrosis, cirrhosis, acute promyelocytic leukaemia (APL), organ transplant rejections, autoimmune diseases, protozoal infections or tumors, which comprises administering an effective amount of the cyclic tetrapeptide compound (I) of claim 1 to a human being or an animal.

Claim 11 (Original): Use of the cyclic tetrapeptide compound (I) of claim 1 for the manufacture of a medicament for treating or preventing inflammatory disorders, diabetes, diabetic complications, homozygous thalassemia, fibrosis, cirrhosis, acute promyelocytic leukaemia (APL), organ transplant rejections, autoimmune diseases, protozoal infections or tumors.

Claim 12 (Original): A commercial package comprising the pharmaceutical composition of claim 9 and a written matter associated therewith, the written matter stating that the pharmaceutical composition may or should be used for treating or preventing inflammatory disorders, diabetes, diabetic complications, homozygous thalassemia, fibrosis,

cirrhosis, acute promyelocytic leukaemia (APL), organ transplant rejections, autoimmune diseases, protozoal infections or tumors.

Claim 13 (Original): A cyclic tetrapeptide compound of the formula (I):



wherein

R^1 is hydrogen,

R^2 is ar(lower)alkyl optionally substituted with one or more suitable substituent(s),

R^3 and R^4 are each hydrogen or lower alkyl, or

R^3 and R^4 are linked together to form lower alkylene,

R^5 is lower alkylene or lower alkenylene,

R^{Y1} is optionally protected hydroxy, and

R^{Y2} is lower alkyl,

providing that, when R^3 is methyl, R^4 is methyl or ethyl, R^5 is pentylene, R^{Y1} is optionally substituted hydroxy and R^{Y2} is methyl, then R^2 is not unsubstituted benzyl, or a salt thereof.

Claim 14 (Original): The cyclic tetrapeptide compound of claim 13, wherein R^2 is phenyl (lower) alkyl optionally substituted with one or more suitable substituent(s) selected from the group consisting of lower alkoxy, ar(lower)alkyloxy, cyano, hydroxy and halogen,


R^3 and R^4 are each lower alkyl, and

R^5 is lower alkylene.

Claim 15 (Original): A pharmaceutical composition containing the cyclic tetrapeptide compound of claim 13 or 14 as an active ingredient, in association with a pharmaceutically acceptable, substantially non-toxic carrier or excipient.

Claim 16 (Original): The cyclic tetrapeptide compound of claim 13 or 14 for use as a medicament.

Claim 17 (Original): A histone deacetylase inhibitor comprising a cyclic tetrapeptide compound of the formula (I'):



wherein

R^1 is hydrogen,

R^2 is ar(lower)alkyl optionally substituted with one or more suitable substituent(s),

R^3 and R^4 are each hydrogen or lower alkyl, or

R^3 and R^4 are linked together to form lower alkylene,

R^5 is lower alkylene or lower alkenylene,

R^{Y1} is optionally protected hydroxy, and

R^{Y2} is lower alkyl,


providing that,

when R^3 is methyl, R^4 is methyl or ethyl, R^5 is pentylene, R^{Y1} is optionally substituted hydroxy and R^{Y2} is methyl, then R^2 is not unsubstituted benzyl, or a salt thereof.

Claim 18 (Original): method for inhibiting histone deacetylase, comprising using a cyclic tetrapeptide compound (I') of claim 17.

Claim 19 (Original): Use of a cyclic tetrapeptide compound (I') of claim 17 for the manufacture of a medicament for inhibiting histone deacetylase.

Claim 20 (Original): A pharmaceutical composition for treating or preventing inflammatory disorders, diabetes, diabetic complications, homozygous thalassemia, fibrosis, cirrhosis, acute promyelocytic leukaemia (APL), organ transplant rejections, autoimmune diseases, protozoal infections or tumors, which comprises, as an active ingredient, a cyclic tetrapeptide compound of the formula (I'):



wherein

R¹ is hydrogen,

R² is ar(lower)alkyl optionally substituted with one or more suitable substituent(s),

R³ and R⁴ are each hydrogen or lower alkyl, or

R³ and R⁴ are linked together to form lower alkylene, R⁵ is lower alkylene or lower alkenylene,

R^{Y1} is optionally protected hydroxy, and

R^{Y2} is lower alkyl,

providing that,

when R³ is methyl, R⁴ is methyl or ethyl, R⁵ is pentylene, R^{Y1} is optionally substituted hydroxy and R^{Y2} is methyl, then R² is not unsubstituted benzyl, or a salt thereof.

Claim 21 (Original): A method for treating or preventing inflammatory disorders, diabetes, diabetic complications, homozygous thalassemia, fibrosis, cirrhosis, acute promyelocytic leukaemia (APL), organ transplant rejections, autoimmune diseases, protozoal infections or tumors, which comprises administering an effective amount of the cyclic tetrapeptide compound (I') of claim 13 to a human being or an animal.

Claim 22 (Original): Use of the cyclic tetrapeptide compound (I') of claim 13 for the manufacture of a medicament for treating or preventing inflammatory disorders, diabetes, diabetic complications, homozygous thalassemia, fibrosis, cirrhosis, acute promyelocytic leukaemia (APL), organ transplant rejections, autoimmune diseases, protozoal infections or tumors.

Claim 23 (Original): A commercial package comprising the pharmaceutical composition of claim 20 and a written matter associated therewith, the written matter stating that the pharmaceutical composition may or should be used for treating or preventing inflammatory disorders, diabetes, diabetic complications, homozygous thalassemia, fibrosis; cirrhosis, acute promyelocytic leukaemia (APL), organ transplant rejections, autoimmune diseases, protozoal infections or tumors.